Adults expressing ImpL2UAS.cHa under the control of Scer\GAL4repo show neuromuscular junctions with fewer active zones.
Expression of ImpL2Scer\UAS.cHa in adult enterocytes (under the control of Scer\GAL4Myo31DF.PU and limited to the adult stage using Scer\GAL80ts.αTub84B) leads to increased circulating and whole-body trehalose levels, increased hemolymph volume and ovary atrophy.
Overexpression of ImpL2Scer\UAS.cHa via Scer\GAL4hs.PB results in viable flies.
Overexpression of ImpL2Scer\UAS.cHa via Scer\GAL4hs.PB increases female median lifespan, oxidative stress resistance and whole-fly lipid content, while reducing fecundity.
Overexpression of ImpL2Scer\UAS.cHa via RU486-induced Scer\GAL4Act5C.Switch.PR increases both median and maximal lifespan of female flies.
Overexpression of ImpL2Scer\UAS.cHa via RU486-induced Scer\GAL4Act5C.Switch.PR increases oxidative stress resistance of female flies, while reducing fecundity.
Overexpression of ImpL2Scer\UAS.cHa with the pan-neuronal driver Scer\GAL4elav.PLu does not extend lifespan.
Overexpression of ImpL2Scer\UAS.cHa with Scer\GAL4Akh.PG does not extend lifespan.
Overexpression of ImpL2Scer\UAS.cHa via Scer\GAL4Ilp2.215-3 significantly extends both median and maximal lifespan of female flies.
Overexpression of ImpL2Scer\UAS.cHa via RU486-induced Scer\GAL4Switch1.106 significantly extends both median and maximal lifespan of female flies.
Ubiquitous overexpression of ImpL2Scer\UAS.cHa under the control of Scer\GAL4Act5C.PI leads to lethality.
Ubiquitous overexpression of ImpL2Scer\UAS.cHa under the control of Scer\GAL4arm.PS results in flies that are decreased in size and weight.
Overexpression of ImpL2Scer\UAS.cHa under the control of Scer\GAL4arm.PS in somatic clones results in a non-autonomous reduction of cell size.
Overexpression of ImpL2Scer\UAS.cHa driven by Scer\GAL4GMR.PF results in a strong reduction of eye size. These ImpL2Scer\UAS.cHa-overexpressing flies are of normal size.
Flies overexpressing ImpL2Scer\UAS.cHa under the control of Scer\GAL4ppl.PP display a pronounced reduction in body size and their development is delayed by two days.
ImpL2UAS.cHa/Scer\GAL4Act5C.PP is an enhancer of increased cell growth rate phenotype of Pten117
ImpL2UAS.cHa/Scer\GAL4Act5C.PP is an enhancer of increased body size phenotype of Pten117
ImpL2UAS.cHa/Scer\GAL4Act5C.PP is an enhancer of increased cell growth rate | somatic clone phenotype of Pten117
ImpL2UAS.cHa/Scer\GAL4Act5C.PP is an enhancer of increased cell growth rate | somatic clone phenotype of Pten117, mTor2L19
ImpL2UAS.cHa, Scer\GAL4GMR.PF is a suppressor | partially of visible phenotype of InRUAS.cHa, Scer\GAL4GMR.PF
ImpL2UAS.cHa, Scer\GAL4GMR.PF has eye phenotype, enhanceable by Df(3L)AC1/+
ImpL2UAS.cHa, Scer\GAL4Myo31DF.PU, Scer\GAL80ts.αTub84B has hemolymph phenotype, non-suppressible by InRact.UAS, Scer\GAL4Myo31DF.PU
ImpL2UAS.cHa, Scer\GAL4Myo31DF.PU, Scer\GAL80ts.αTub84B has ovary phenotype, non-suppressible by InRact.UAS, Scer\GAL4Myo31DF.PU
ImpL2UAS.cHa, Scer\GAL4GMR.PF is a suppressor | partially of eye phenotype of InRUAS.cHa, Scer\GAL4GMR.PF
Expression of InRact.Scer\UAS does not suppress the increases in circulating and whole-body trehalose levels and hemolymph volume and ovary atrophy seen when ImpL2Scer\UAS.cHa is expressed in adult enterocytes (under the control of Scer\GAL4Myo31DF.PU and limited to the adult stage using Scer\GAL80ts.αTub84B).
Ubiquitous expression of ImpL2Scer\UAS.cHa (under the control of Scer\GAL4Act5C.PP) results in the overgrowth of Pten117 clones, irrespective of whether they neighbor Tor2L19 mutant or wild-type cells. The overgrowth of Pten117 clones causes a further reduction in body size, as evidenced by decreased shoulder width.
ImpL2Scer\UAS.cHa partially suppresses the eye overgrowth resulting from the overexpression of InRScer\UAS.cHa driven by Scer\GAL4GMR.PF.
Df(3L)AC1 dominantly enhances the small eye phenotype caused by Scer\GAL4GMR.PF-driven overexpression of ImpL2Scer\UAS.cHa.